AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30026032 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of major abnormalities
Number of subjects: 3517
Study 30026032 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccination
Number of subjects: 3517
Study 30026032 — intervention group
Group type: EXPERIMENTAL
Intervention: Major abnormalities
Number of subjects: 3517
Study 30026059 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 or 750 mg daily)
Number of subjects: 40
Study 30026059 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (after progression)
Number of subjects: 40
Study 30026110 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib (200 mg/day)
Number of subjects: 37
Study 30026177 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (SMS) intervention
Number of subjects: 132
Study 30026275 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (GLP-1 agonist), dosage and duration not specified
Number of subjects: 0
Study 30026783 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 675
Study 30026783 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal dialysis (PD)
Number of subjects: 675
Study 30026784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric nutritional intervention for 6 months
Number of subjects: 33
Study 30026785 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil intake
Number of subjects: 149
Study 30026787 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC)
Number of subjects: 108
Study 30026787 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 108
Study 30026911 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-platform information and communication technology intervention for neonatal resuscitation training
Number of subjects: 0
Study 30026911 — intervention group
Group type: COMPARATOR
Intervention: Standard training for neonatal resuscitation
Number of subjects: 0
Study 30026911 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-platform information and communication technology intervention for neonatal resuscitation training; details on dosage and duration not available.
Number of subjects: 0
Study 30026911 — intervention group
Group type: COMPARATOR
Intervention: Standard training for neonatal resuscitation; details on dosage and duration not available.
Number of subjects: 0
Study 30026938 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia
Number of subjects: 0
Study 30026938 — intervention group
Group type: COMPARATOR
Intervention: No thoracic epidural analgesia
Number of subjects: 0
Study 30027002 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg chewable tablets
Number of subjects: 220
Study 30027002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 30027104 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets 3.5 mg/kg/IFN-β
Number of subjects: 172
Study 30027104 — intervention group
Group type: COMPARATOR
Intervention: Placebo/IFN-β
Number of subjects: 172
Study 30027121 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based home exercise program using PT PAL, 3 times a week for 6 months
Number of subjects: 21
Study 30027121 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based home exercise program using PT PAL
Number of subjects: 21
Study 30027121 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology support such as text reminders
Number of subjects: 21
Study 30027478 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan 5 mg (for patients <50 kg)
Number of subjects: 6
Study 30027478 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan 10 mg (for patients ≥50 kg)
Number of subjects: 6
Study 30027668 — intervention group
Group type: EXPERIMENTAL
Intervention: Migration (changes of residence over geopolitical boundaries)
Number of subjects: 1919
Study 30027668 — intervention group
Group type: EXPERIMENTAL
Intervention: Labour-related mobility
Number of subjects: 1919
Study 30027668 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-labour-related mobility
Number of subjects: 1919
Study 30027687 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing services
Number of subjects: 148
Study 30027687 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 148
Study 30027687 — intervention group
Group type: EXPERIMENTAL
Intervention: Health service interactions
Number of subjects: 148
Study 30027782 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum in the head-up position
Number of subjects: 28
Study 30027782 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurement
Number of subjects: 28
Study 30028037 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib combined with 5-azacytidine (AZA)
Number of subjects: 27
Study 30028985 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR intraoperative imaging using TumorGlow (high-dose indocyanine green and delayed imaging)
Number of subjects: 20
Study 30028985 — intervention group
Group type: EXPERIMENTAL
Intervention: NIR intraoperative imaging using TumorGlow
Number of subjects: 20
Study 30029627 — intervention group
Group type: EXPERIMENTAL
Intervention: COGNITUS & MOI program
Number of subjects: 0
Study 30029627 — intervention group
Group type: COMPARATOR
Intervention: Motor skill and video viewing intervention
Number of subjects: 0
Study 30029674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from patients with UC
Number of subjects: 0
Study 30029674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from patients with CD
Number of subjects: 0
Study 30029674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from patients with CD and axSpA
Number of subjects: 0
Study 30029674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from patients with axSpA
Number of subjects: 0
Study 30029674 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraepithelial lymphocytes (IELs) from all disease subtypes
Number of subjects: 0
Study 30029674 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 30029855 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivacaftor treatment for 3 months
Number of subjects: 23
Study 30029866 — intervention group
Group type: EXPERIMENTAL
Intervention: WTC Health Registry participants (n=180)
Number of subjects: 402
Study 30029866 — intervention group
Group type: EXPERIMENTAL
Intervention: Dust cloud exposure
Number of subjects: 402
Study 30029866 — intervention group
Group type: EXPERIMENTAL
Intervention: Home dust exposure
Number of subjects: 402
Study 30029866 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (n=222)
Number of subjects: 402
Study 30030011 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid decline in estimated glomerular filtration rate over 2 years
Number of subjects: 0
Study 30030617 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary adiponectin in patients with SS
Number of subjects: 17
Study 30030617 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary ADA in patients with SS
Number of subjects: 17
Study 30030617 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary ADA in patients with non-SS sicca
Number of subjects: 17
Study 30031087 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30031399 — intervention group
Group type: EXPERIMENTAL
Intervention: Large follicles
Number of subjects: 184
Study 30031399 — intervention group
Group type: COMPARATOR
Intervention: Small follicles
Number of subjects: 184
Study 30031399 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene expression of HAS2 and GDF9
Number of subjects: 184
Study 30031399 — intervention group
Group type: EXPERIMENTAL
Intervention: Other gene expressions studied (TNFAIP6, PTGS2, PTX3)
Number of subjects: 184
Study 30031556 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation with intramuscular injection (olanzapine, droperidol, haloperidol, benzodiazepine, ketamine)
Number of subjects: 1146
Study 30031556 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical events observed in agitated patients
Number of subjects: 1146
Study 30031556 — intervention group
Group type: EXPERIMENTAL
Intervention: Delirium symptoms
Number of subjects: 1146
Study 30031556 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics associated with clinical events
Number of subjects: 1146
Study 30031700 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 324
Study 30031719 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardiac monitor (Reveal XT, Reveal Linq) implanted at 4 (3 to 6) days post-TAVR, continuous ECG monitoring for 12 months
Number of subjects: 103
Study 30031863 — intervention group
Group type: EXPERIMENTAL
Intervention: Inorganic nitrate supplementation
Number of subjects: 0
Study 30031863 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline
Number of subjects: 0
Study 30031863 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate supplementation
Number of subjects: 0
Study 30032103 — intervention group
Group type: EXPERIMENTAL
Intervention: Work-focused cognitive-behavioural therapy and individual job support
Number of subjects: 1193
Study 30032103 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1193
Study 30032306 — intervention group
Group type: COMPARATOR
Intervention: Ischemia (IS) group
Number of subjects: 165
Study 30032306 — intervention group
Group type: EXPERIMENTAL
Intervention: Human study (acute phase)
Number of subjects: 165
Study 30032426 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-albuminuric renal impairment
Number of subjects: 15773
Study 30032426 — intervention group
Group type: COMPARATOR
Intervention: Albuminuric forms of diabetic kidney disease (DKD)
Number of subjects: 15773
Study 30032814 — intervention group
Group type: EXPERIMENTAL
Intervention: Avitinib (150-300 mg) twice daily for cycles of 28 days
Number of subjects: 16
Study 30032875 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol management of neuromuscular block with neostigmine reversal
Number of subjects: 78
Study 30032875 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 78
Study 30032887 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine 0.25%, 20 ml with epinephrine 5 μg/ml
Number of subjects: 23
Study 30032887 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy male volunteers)
Number of subjects: 23
Study 30033559 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-exposure prophylaxis (PrEP)
Number of subjects: 0
Study 30033559 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP offered to high-risk MSM
Number of subjects: 0
Study 30033559 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP
Number of subjects: 0
Study 30033644 — intervention group
Group type: EXPERIMENTAL
Intervention: Online group (online counselling and online, supervised, HIV self-testing)
Number of subjects: 571
Study 30033644 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed group (online pre-test counselling and offline HIV testing)
Number of subjects: 571
Study 30033644 — intervention group
Group type: COMPARATOR
Intervention: Offline group (offline HIV counselling and testing)
Number of subjects: 571
Study 30033738 — intervention group
Group type: COMPARATOR
Intervention: Placebo group from a previous randomized trial
Number of subjects: 6
Study 30035000 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD group
Number of subjects: 21
Study 30035000 — intervention group
Group type: COMPARATOR
Intervention: TD group
Number of subjects: 21
Study 30035584 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent self-weighing
Number of subjects: 762
Study 30035584 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent self-weighing combined with binge eating
Number of subjects: 762
Study 30036361 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-based mindfulness meditation program
Number of subjects: 53
Study 30036892 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle aspiration (FNA) of benign lymph nodes, with a minimum of three passes.
Number of subjects: 27
Study 30036892 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle aspiration (FNA)
Number of subjects: 27
Study 30037302 — intervention group
Group type: EXPERIMENTAL
Intervention: E-liac Stent Graft System
Number of subjects: 45
Study 30037339 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and supervised exercise (information from a physiotherapist and individually adapted exercises)
Number of subjects: 264
Study 30037339 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and supervised exercise
Number of subjects: 264
Study 30037339 — intervention group
Group type: COMPARATOR
Intervention: Standard care (reference group)
Number of subjects: 264
Study 30037629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation with documented time to pulmonary vein isolation (Group 1)
Number of subjects: 1042
Study 30037629 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation without documented time to pulmonary vein isolation (Group 2)
Number of subjects: 1042
Study 30037629 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 1042
Study 30037651 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMS (Helicopter Emergency Medical Services)
Number of subjects: 33
Study 30037651 — intervention group
Group type: COMPARATOR
Intervention: Control (patients presenting directly to the Comprehensive Stroke Center)
Number of subjects: 33
Study 30037888 — intervention group
Group type: EXPERIMENTAL
Intervention: CVDPoRT algorithm
Number of subjects: 104219
Study 30038037 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial therapy (EAT) including vancomycin and broad-spectrum beta-lactam
Number of subjects: 333
Study 30038037 — intervention group
Group type: EXPERIMENTAL
Intervention: Empirical antimicrobial therapy (EAT)
Number of subjects: 333
Study 30038051 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fat intake after colon cancer diagnosis
Number of subjects: 0
Study 30038051 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30038390 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined-intensified-modulated-adjuvant treatment including RT and hormone therapy (HT) after RP.
Number of subjects: 123
Study 30038658 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 32
Study 30038669 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of LBP (Q4)
Number of subjects: 482
Study 30038669 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist circumference criterion met
Number of subjects: 482
Study 30038669 — intervention group
Group type: EXPERIMENTAL
Intervention: LBP
Number of subjects: 482
Study 30038669 — intervention group
Group type: EXPERIMENTAL
Intervention: LBP and sCD14
Number of subjects: 482
Study 30038793 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PM+ intervention
Number of subjects: 0
Study 30038793 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30038794 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal frailty intervention (tailored exercise program, protein supplementation, vitamin D supplementation, medication review)
Number of subjects: 0
Study 30038794 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 30038794 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-modal frailty intervention
Number of subjects: 0
Study 30039172 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCE) for ASCVD risk prediction
Number of subjects: 19995
Study 30039172 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCE) with CMS event linkage
Number of subjects: 19995
Study 30039172 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled Cohort Equations (PCE) overall
Number of subjects: 19995
Study 30039554 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilteritinib (20 to 300 mg/d, once daily)
Number of subjects: 24
Study 30039634 — intervention group
Group type: EXPERIMENTAL
Intervention: Brexpiprazole 1 to 3 mg/day adjunct to current ADT
Number of subjects: 132
Study 30040065 — intervention group
Group type: EXPERIMENTAL
Intervention: mpMRI
Number of subjects: 576
Study 30040065 — intervention group
Group type: COMPARATOR
Intervention: TRUS-guided biopsy
Number of subjects: 576
Study 30040065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of mpMRI-based pathway
Number of subjects: 576
Study 30040168 — intervention group
Group type: EXPERIMENTAL
Intervention: Prexasertib (80 mg/m)
Number of subjects: 0
Study 30041608 — intervention group
Group type: EXPERIMENTAL
Intervention: Conbercept
Number of subjects: 5000
Study 30041614 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (4 cycles)
Number of subjects: 0
Study 30041614 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (4 cycles)
Number of subjects: 0
Study 30041614 — intervention group
Group type: COMPARATOR
Intervention: Surgery followed by adjuvant chemotherapy (reference treatment)
Number of subjects: 0
Study 30041626 — intervention group
Group type: COMPARATOR
Intervention: Traditional exercise (active control)
Number of subjects: 100
Study 30041626 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored exercise
Number of subjects: 100
Study 30041685 — intervention group
Group type: EXPERIMENTAL
Intervention: CO-IMPACT intervention
Number of subjects: 240
Study 30041685 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual primary care
Number of subjects: 240
Study 30041785 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment
Number of subjects: 654
Study 30041962 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation therapy (NCRT)
Number of subjects: 106
Study 30041962 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomics profiling
Number of subjects: 106
Study 30041971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine release capacity measured by percent change in baseline binding potential relative to nondisplaceable compartment (ΔBP)
Number of subjects: 26
Study 30041971 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison participants
Number of subjects: 26
Study 30042063 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard DCF regimen
Number of subjects: 66
Study 30042063 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified DCF regimen
Number of subjects: 66
Study 30042063 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (both regimens)
Number of subjects: 66
Study 30042144 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensed MCMDM-1 VWD
Number of subjects: 120
Study 30042144 — intervention group
Group type: COMPARATOR
Intervention: ISTH BAT
Number of subjects: 120
Study 30042673 — intervention group
Group type: EXPERIMENTAL
Intervention: Choral singing intervention
Number of subjects: 0
Study 30042675 — intervention group
Group type: COMPARATOR
Intervention: RTI-336
Number of subjects: 0
Study 30042675 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30043115 — intervention group
Group type: EXPERIMENTAL
Intervention: Florbetaben injection (222-318.2 MBq, mean 270.1 ± 33.3 MBq)
Number of subjects: 9
Study 30043168 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS)
Number of subjects: 174
Study 30043168 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery (CLS)
Number of subjects: 174
Study 30043210 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks with methotrexate
Number of subjects: 132
Study 30043210 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP)
Number of subjects: 132
Study 30044478 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance for stage I seminoma (89 patients, 57.8%)
Number of subjects: 299
Study 30044478 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for stage I seminoma (65 patients, 42.2%)
Number of subjects: 299
Study 30044478 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy for high-risk stage I non-seminoma (23 patients)
Number of subjects: 299
Study 30044478 — intervention group
Group type: EXPERIMENTAL
Intervention: Active surveillance for low-risk stage I non-seminoma (30 patients, 100%)
Number of subjects: 299
Study 30044478 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy for stage II seminoma (12 patients, 46.2%)
Number of subjects: 299
Study 30044478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for stage II seminoma (14 patients, 53.8%)
Number of subjects: 299
Study 30044478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for stage III seminoma (all patients)
Number of subjects: 299
Study 30044478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for stage II and III non-seminoma (all patients)
Number of subjects: 299
Study 30044478 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compliance with guidelines (11 patients)
Number of subjects: 299
Study 30044692 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib monotherapy
Number of subjects: 0
Study 30044693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified treatment for IKZF1 deletion
Number of subjects: 0
Study 30044693 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 30044695 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral prophylactic mastectomy (CPM)
Number of subjects: 288
Study 30044695 — intervention group
Group type: COMPARATOR
Intervention: No contralateral prophylactic mastectomy (non-CPM)
Number of subjects: 288
Study 30045714 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Mindfulness-Based Intervention (MYmind): 8-week group-based MBI for youth combined with parallel group-based Mindful Parenting for parents, as an add-on to care-as-usual (CAU)
Number of subjects: 100
Study 30045714 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU) only
Number of subjects: 100
Study 30045714 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Mindfulness-Based Intervention (MYmind)
Number of subjects: 100
Study 30045729 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared Latrines (SL)
Number of subjects: 96